EGFR, NF-κB and noncoding RNAs in precision medicine

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cancer remains a leading cause of mortality, necessitating advancements in treatment.
• Precision medicine has significantly improved tumor treatment efficiency.
• Targeted therapy and immunotherapy are key strategies in precision cancer care.

Purpose of the Study:

• To summarize the roles of epidermal growth factor receptor (EGFR) in cancer.
• To elucidate the involvement of NF-κB signaling in carcinogenesis.
• To review the regulatory functions of non-coding RNAs (ncRNAs) in cancer treatment and drug efficacy.

Main Methods:

• Literature review and synthesis of existing research on EGFR, NF-κB, and ncRNAs in cancer.
• Analysis of the mechanisms by which these factors influence cancer development and treatment response.

Main Results:

• EGFR targeting is a crucial component of targeted cancer therapy.
• NF-κB signaling pathways are significantly implicated in the initiation and progression of cancer.
• Non-coding RNAs (ncRNAs) emerge as critical regulators in carcinogenesis and modulators of anticancer drug effectiveness.

Conclusions:

• Understanding the interplay between EGFR, NF-κB, and ncRNAs is vital for advancing precision cancer medicine.
• Targeted inhibition of EGFR and modulation of NF-κB pathways hold therapeutic potential.
• ncRNAs represent promising targets and biomarkers for improving cancer treatment outcomes.